Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Biotechnol Prog. 2021 Jul;37(4):e3158. doi: 10.1002/btpr.3158. Epub 2021 May 12.
Site specific integration (SSI) expression systems offer robust means of generating highly productive and stable cell lines for traditional monoclonal antibodies. As complex modalities such as antibody-like molecules comprised of greater than two peptides become more prevalent, greater emphasis needs to be placed on the ability to produce appreciable quantities of the correct product of interest (POI). The ability to screen several transcript stoichiometries could play a large role in ensuring high amounts of the correct POI. Here we illustrate implementation of an SSI expression system with a single site of integration for development and production of a multi-chain, bi-specific molecule. A SSI vector with a single copy of all of the genes of interest was initially selected for stable Chinese hamster ovary transfection. While the resulting transfection pools generated low levels of the desired heterodimer, utilizing an intensive clone screen strategy, we were able to identify clones having significantly higher levels of POI. In-depth genotypic characterization of clones having the desirable phenotype revealed that a duplication of the light chain within the landing pad was responsible for producing the intended molecule. Retrospective transfection pool analysis using a vector configuration mimicking the transgene configuration found in the clones, as well as other vector configurations, yielded more favorable results with respect to % POI. Overall, the study demonstrated that despite the theoretical static nature of the SSI expression system, enough heterogeneity existed to yield clones having significantly different transgene phenotypes/genotypes and support production of a complex multi-chain molecule.
位点特异性整合 (SSI) 表达系统为生产传统单克隆抗体提供了高效、稳定的细胞系的有力手段。随着由两个以上肽段组成的类似抗体的复杂分子等越来越多的出现,需要更加注重生产大量目标产物(POI)的能力。筛选几种转录物化学计量比的能力在确保大量正确 POI 方面可能发挥重要作用。本文介绍了一种 SSI 表达系统的实现,该系统在单个整合位点用于开发和生产多链、双特异性分子。最初选择了一个带有所有感兴趣基因的单个拷贝的 SSI 载体进行稳定的中国仓鼠卵巢转染。虽然产生的转染池产生了低水平的所需杂二聚体,但通过密集的克隆筛选策略,我们能够鉴定出具有明显更高 POI 水平的克隆。对具有所需表型的克隆进行深入的基因型特征分析表明,在着陆垫内轻链的重复是产生预期分子的原因。使用类似于克隆中转基因构型的载体构型以及其他载体构型对转染池进行回顾性分析,在 POI%方面产生了更有利的结果。总的来说,该研究表明,尽管 SSI 表达系统具有理论上的静态性质,但存在足够的异质性,可以产生具有明显不同转基因表型/基因型的克隆,并支持复杂多链分子的生产。